IBI397 or Combination Therapies in Patients With Advanced Malignancies
A Phase Ia/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IBI397 or Combination Therapies in Patients With Advanced Malignancies
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Lili Tan
- Phone Number: 15901474796
- Email: lili.tan@innoventbio.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300200
- Tianjin Medical University Cancer Institute and Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Have failed the standard treatment for locally advanced, recurrent or metastatic solid tumor or have failed at least the second line standard treatment (including autologous stem cell transplantation) or have failed the first line standard treatment and are not eligible for autologous stem cell transplantation
- Willing to and able to provide written informed consent for the trial and able to comply with protocol-specified visits and related procedures
- ≥ 18 and ≤ 75 years of age on the day of signing the informed consent
- Have a performance scale of 0 or 1 on the Eastern Cooperative Oncology Group Performance Status (ECOG PS)
- Subjects with solid tumor: Have at least one measurable or assessable lesion as defined by RECIST v1.1; Subjects with lymphoma: Have at least one measurable or assessable lesion as defined by Lugano2014 criteria
Exclusion Criteria:
- Has been previously exposed to any CD47 antibody, SIRPα antibody, or CD47/SIRPα recombinant protein or other inhibitors that target the same pathway
- Is currently participating in another interventional study, except for observational (non-interventional) study or in the survival follow-up phase of an interventional study
- Requires long-term systemic hormone or any other immunosuppressive drug therapy, excluding inhaled hormone therapy
- Has acute or chronic active hepatitis B (defined as hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody positive [HBcAb] and hepatitis B virus [HBV] DNA copy number ≥ 1 × 104 copies/ml or ≥ 2000 IU/ml or higher than the lower limit of detection) or acute or chronic active hepatitis C virus (HCV) antibody positive; HCV antibody positive but RNA negative subjects are allowed
- Has a known history of severe allergic reaction to other monoclonal antibodies, or is allergic to any component of the IBI397 formulation.
- Is pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IBI397 single-agent dose escalation
|
IBI397 single-agent dose escalation: Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
|
|
Experimental: IBI397+ Rituximab
|
IBI397 single-agent dose escalation: Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
IBI397 in combination with rituximab: Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
|
|
Experimental: IBI397 + Sintilimab
|
IBI397 single-agent dose escalation: Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
IBI397 in combination with sintilimab: Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with treatment related AEs
Time Frame: Up to 90 days post last dose
|
Number of patients who experienced a treatment related AEs from the frist dose until 90 days after the last dose
|
Up to 90 days post last dose
|
|
Percentage of Subjects with Dose-Limiting Toxicities (DLTs)
Time Frame: Up to 28 Days following first dose
|
To evaluate the safety and tolerability of IBI397 alone or in combination with Sintilimab
|
Up to 28 Days following first dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
area under the plasma concentration-time curve (AUC)
Time Frame: Up to 90 days post last dose
|
Up to 90 days post last dose
|
|
|
maximum concentration (Cmax)
Time Frame: Up to 90 days post last dose
|
Up to 90 days post last dose
|
|
|
clearance (CL)
Time Frame: Up to 90 days post last dose
|
Up to 90 days post last dose
|
|
|
volume of distribution (V)
Time Frame: Up to 90 days post last dose
|
Up to 90 days post last dose
|
|
|
half-life (t1/2)
Time Frame: Up to 90 days post last dose
|
Up to 90 days post last dose
|
|
|
anti-drug antibody (ADA)
Time Frame: Up to 90 days post last dose
|
Number of Anti-Drug Antibodies (ADA) positive subjects will be counted and percentage of ADA positive subjects will be calculated to evaluate immunogenicity of IBI397
|
Up to 90 days post last dose
|
|
Objective response rate (ORR)
Time Frame: Up to 2 years after enrollment
|
Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response (PR) assessed per RECIST v1.1 criteria for solid tumors or per Lugano2014 criteria for lymphomas
|
Up to 2 years after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIBI397A101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.